Sign In
Buy NVO
$47.41
-0.0100 (-0.0211%)
At Close: Jun 24, 2026
Novo Nordisk, Chewy And FedEx Are Among Top 10 Large Cap Losers Last Week (Sept 15-Sept 21): Are The Others In Your Portfolio?
05:04pm, Sunday, 22'nd Sep 2024
These ten large-cap stocks were the worst performers in the last week. Are they in your portfolio?
3 Stocks That Could Rise on European Bank Interest Rate Cuts
07:01am, Sunday, 22'nd Sep 2024
U.S. stocks reacted positively following the Federal Open Market Committee's announcement in mid-September that it would lower interest rates by 50 basis points, wider than many analysts had anticipat
Why Novo Nordisk Stock Fell While Eli Lilly and Viking Therapeutics Bumped Higher Today
06:14pm, Friday, 20'th Sep 2024
The latest news from the Danish drug developer was not encouraging. Its experimental weight loss drug produced results, but also a set of side effects.
Novo Nordisk Sinks on Obesity Drug Study's Disappointing Results
03:05pm, Friday, 20'th Sep 2024
Novo Nordisk's (NVO) U.S.-listed shares lost ground Friday after a study of the pharmaceutical firm's latest obesity treatment showed less effectiveness in higher doses.
NVO Gets Positive CHMP Opinion for Wegovy's Label Update in EU
12:06pm, Friday, 20'th Sep 2024
Novo Nordisk receives a positive opinion from the CHMP for a label update of Wegovy to reflect reduced heart failure symptoms and improved physical function.
NVO Stock Loses Around $29B in 3 Months: Buy the Dip or Steer Clear?
12:06pm, Friday, 20'th Sep 2024
Despite the current downward trend of Novo Nordisk, it is an excellent stock to buy for long-term gains, driven by the stellar performance of its GLP-1 drugs.
Novo Nordisk shares drop more than 4% on disappointing obesity pill data
10:11am, Friday, 20'th Sep 2024
Novo Nordisk fell more than 4% on Friday to their lowest level since Aug. 10 after the Danish drugmaker reported results from a Phase 2a trial of its experimental obesity pill monlunabant that came in
Novo's Wegovy Backed by EU Regulator For Obesity-Related Heart Conditions. FDA Could Be Next.
08:46am, Friday, 20'th Sep 2024
The blockbuster drug strengthens its case that obesity drugs have health benefits beyond weight-loss.
Novo Nordisk A/S: Monlunabant phase 2a trial in obesity successfully completed
08:43am, Friday, 20'th Sep 2024
Bagsværd, Denmark, 20 September 2024 – Novo Nordisk today announced headline results from a phase 2a clinical trial with monlunabant, a small molecule oral cannabinoid receptor 1 (CB1) inverse agon
EU regulator backs use of Novo's Wegovy for obesity-related heart condition
03:38pm, Thursday, 19'th Sep 2024
The European Medicines Agency backed the use of Novo Nordisk's Wegovy in patients with an obesity-related heart condition, the Danish drugmaker said on Thursday.
Wegovy ® recommended by the European regulatory authorities for label update to reflect reduced heart failure symptoms and improved physical function
Novo Nordisk: The Street Is Not Seeing The Growth Acceleration Potential
12:40pm, Thursday, 19'th Sep 2024
Novo Nordisk A/S's shares have stalled recently, but this looks like a natural digestion of gains from prior years. Supply constraints for the obesity business are easing, and we should see growth pic
Novo Nordisk Just Took a $530 Million Step Onto Moderna's Turf. Here's What It Means for Both Stocks
06:50am, Thursday, 19'th Sep 2024
Novo Nordisk and Korro Bio just signed a big collaboration deal. The pair aim to develop medicines involving mRNA, which is Moderna's specialty.
Multiple Strong Catalysts And Attractive Valuation Make Novo Nordisk A Buy
12:02pm, Wednesday, 18'th Sep 2024
Novo Nordisk's weight-loss drugs, Ozempic and Wegovy, have multiple positive catalysts, making NVO stock attractive for medium-to-long term investors. Insurance coverage for Ozempic and Wegovy may be
Novo says Ozempic 'very likely' to be on 2027 Medicare negotiation list, Bloomberg News reports
07:17pm, Tuesday, 17'th Sep 2024
Danish drugmaker Novo Nordisk expects its diabetes drug Ozempic will "very likely" be on the U.S. government's 2027 list of price negotiations, Bloomberg News reported on Tuesday citing a company exec
